Abetimus

Identification

Name
Abetimus
Accession Number
DB06662
Type
Biotech
Groups
Investigational
Biologic Classification
Nucleic Acid Based Therapies
Oligonucleotides
Description

Abetimus is an immunosuppressant developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Abetimus sodiumF5Y7739G6U169147-32-4Not applicable
International/Other Brands
Riquent
Categories
UNII
P3UVQ22SHK
CAS number
167362-48-3

Pharmacology

Indication

Investigated for use/treatment in kidney disease and systemic lupus erythematosus.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Abetimus.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Abetimus.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abetimus.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abetimus.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Abetimus.Approved
FingolimodAbetimus may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Abetimus.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Abetimus.Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Abetimus.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Abetimus.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Abetimus.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Abetimus.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Abetimus is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Abetimus is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Abetimus.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Abetimus is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Abetimus.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Abetimus.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Abetimus.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Abetimus.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abetimus.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Abetimus.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Abetimus.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Abetimus.Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Abetimus.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Abetimus.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Abetimus.Investigational
TofacitinibAbetimus may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Abetimus.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Abetimus.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Abetimus.Approved
Food Interactions
Not Available

References

General References
  1. Authors unspecified: Abetimus: Abetimus sodium, LJP 394. BioDrugs. 2003;17(3):212-5. [PubMed:12749759]
  2. Wallace DJ: Clinical and pharmacological experience with LJP-394. Expert Opin Investig Drugs. 2001 Jan;10(1):111-7. [PubMed:11116284]
External Links
Wikipedia
Abetimus
ATC Codes
L04AA22 — Abetimus

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnDiagnosticSystemic Lupus Erythematosus (SLE)1
3CompletedTreatmentAutoimmune Diseases / Immunologic Diseases / Lupus Glomerulonephritis / Nephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
3TerminatedTreatmentLupus Erythematosus, Systemic / Nephritis, Lupus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:46 / Updated on November 27, 2017 10:43